Compare iShares MSCI Taiwan ETF (EWT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Tango Therapeutics Inc. — how do they compare? iShares MSCI Taiwan ETF trades at $107.33 (market cap $12.49B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: iShares MSCI Taiwan ETF is far larger — about 3.3× Tango Therapeutics Inc.'s market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 53 Days and Tango Therapeutics Inc. for 0 Days on average.
| EWT | TNGX | |
|---|---|---|
Market Cap | $12.49B | $3.75B |
Volume | 5,965,495 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $32.90 |
52-Week Low | $60.03 | $7.50 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $113.46, down 0.71% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, which represents 22.5% of holdings. Recent news highlights Taiwan's strategic position in AI chip manufacturing with companies planning $20 billion in US investments.
The ETF offers exposure to Taiwan's dominant semiconductor industry but faces significant geopolitical risks. Strong AI-driven fundamentals and reasonable tech valuations support upside potential, though China-Taiwan tensions represent a persistent overhang. Institutional interest remains positive with Bank of America increasing its stake by 22.4% in the latest quarter.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
